Progressive Multifocal Leukoencephalopathy (PML - Asymmetric U-Fiber & IRIS Protocol)

• Seen in severely immunocompromised adults (most commonly aged 30–60 years):
• (1)
  HIV/AIDS patients (historically the most common cohort, typically CD4 count <100–200 cells/uL);
• (2)
  patients with Multiple Sclerosis receiving disease-modifying monoclonal antibody therapy
• (3)
  organ transplant recipients or hematological malignancies on Rituximab. Presents with subacute, progressive, multifocal neurological deficits: cognitive decline, aphasia, visual field loss (homonymous hemianopia), ataxia, and hemiparesis, typically in the absence of fever.
• Caused by opportunistic demyelinating infection of the central nervous system caused by reactivation of the neurotropic human polyomavirus John Cunningham Virus (JC Virus):
• (1)
  Pathogenesis: Latent JC virus (present in 60–80% of healthy adults in kidney and lymphoid tissue) reactivates during severe cellular immunocompromise, crossing the blood-brain barrier and selectively infecting and destroying oligodendrocytes
• (2)
  Histopathological Triad: (1) Multifocal demyelination; (2) enlarged, dysmorphic oligodendrocytes containing basophilic viral inclusion bodies; and (3) bizarre, pleomorphic, multinucleated giant astrocytes.
• (3)
  Immune Reconstitution Inflammatory Syndrome (PML-IRIS): Paradoxical, life-threatening hyperinflammatory surge following restoration of the immune system (starting antiretroviral therapy [ART] in HIV or plasma exchange to remove Natalizumab), causing intense contrast enhancement, mass effect, and cerebral edema.

Imaging Findings

• Magnetic Resonance Imaging (Brain MRI - Diagnostic Gold Standard Framework):
• –
  Classic Pre-IRIS PML Findings:
• 1.
  Asymmetric, Confluent, Multifocal White Matter Lesions: Symmetrical or characteristically strikingly asymmetric, scalloped, well-demarcated demyelinating lesions involving the subcortical and deep white matter (parieto-occipital and frontal lobes predominate).
• 2.
  Involvement of Subcortical U-Fibers: Lesions characteristically abut and invade the arcuate subcortical U-fibers, creating a sharp, scalloped border against the overlying uninvolved cerebral cortex.
• 3.
  T1WI Hypointensity: Deeply hypointense ('burnt sugar' appearance) reflecting severe, true demyelinating tissue destruction (unlike multiple sclerosis plaques which are typically milder isointense/hypointense).
• 4.
  T2WI / FLAIR: Confluent, brilliant hyperintensity with a characteristic 'scalloped' outer margin bordering cortex.
• 5.
  Striking Absence of Mass Effect & Absence of Contrast Enhancement: Classic PML is characterized by total absence of mass effect, absence of surrounding vasogenic edema, and absence of contrast enhancement, reflecting the complete lack of host immune response.
• 6.
  Diffusion-Weighted Imaging (DWI): Active, advancing peripheral margin shows hyperintensity on DWI with restricted diffusion (low ADC), representing active viral oligodendrocyte lysis.
• –
  PML-IRIS Findings (Post-Immune Recovery Surge):
• 1.
  Prominent, robust contrast enhancement (patchy, nodular, or linear) along the lesion margins.
• 2.
  Development of marked vasogenic edema and mass effect with sulcal and ventricular compression.
• –
  DWI / ADC: Classic centrifugal pattern—the peripheral advancing demyelinating edge shows a thin rim of true diffusion restriction (high DWI, low ADC) where oligodendrocytes are actively lysed, while the central burnt-out white matter core shows facilitated diffusion (low DWI, high ADC).
• –
  **SWI / T2* GRE: Frequently demonstrates a thin, linear hypointense band of susceptibility blooming along the deep cortical layers / leukocortical junction** adjacent to PML lesions (representing iron accumulation within macrophages).

Differential Diagnosis

Important Points to Remember

• Diagnostic Pitfall: Missing the development of PML-IRIS and failing to initiate corticosteroids, or mistaking the contrast enhancement of IRIS for a brain tumor/abscess! While classic PML strictly DOES NOT enhance, when immune function recovers (e.g. initiating ART in HIV or plasma exchange in Natalizumab-treated MS), the recovering T-cells mount an explosive inflammatory attack on the virus (PML-IRIS). New contrast enhancement and mass effect in a PML patient is NOT treatment failure or a new tumor; it is PML-IRIS, which demands urgent high-dose systemic corticosteroid therapy to prevent fatal herniation.
• Crucial Review Areas:
• 1.
  Subcortical U-fibers on axial T2/FLAIR: sharp scalloped margin directly abutting the cortex confirms PML.
• 2.
  T1-weighted images: deep hypointensity ('burnt' tissue destruction) differentiating PML from HIV encephalopathy.
• 3.
  Active advancing leading edge on DWI: restricted diffusion at the outer rim indicates active viral cytopathy.
• 4.
  Post-contrast T1WI: absence of enhancement confirms classic PML; new intense enhancement with edema indicates life-threatening PML-IRIS.
• Radiologist Safe Practice & Management:
• 1.
  Diagnostic Verification: High-sensitivity quantitative Polymerase Chain Reaction (PCR) for JC virus DNA in cerebrospinal fluid (CSF) via lumbar puncture (sensitivity >95% in untreated patients).
• 2.
  Immediate Drug Discontinuation & Clearance: In MS patients on Natalizumab, immediately discontinue the drug and perform 3–5 cycles of Plasma Exchange (PLEX) or immunoadsorption to accelerate clearance of circulating antibody.
• 3.
  Immune Restoration (HIV Patients): Immediate optimization and initiation of Combination Antiretroviral Therapy (cART) to boost CD4 count and restore cellular immunity (the only effective therapy for HIV-associated PML).
• 4.
  Corticosteroid Therapy for PML-IRIS: High-dose intravenous corticosteroids (IV Methylprednisolone 1 g/day for 5 days followed by oral taper) immediately upon radiological or clinical signs of PML-IRIS.
• 5.
  Serial MRI Monitoring: Baseline and serial brain MRI every 4–8 weeks to monitor lesion stabilization, assess for IRIS development, and detect asymptomatic rebound MS activity.